Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Study of the Efficacy and Safety of Pirfenidone vs. Nintedanib in the Treatment of Fibrotic Lung Disease After Coronavirus Disease-19 Pneumonia

NCT04856111 is registered in ClinicalTrials.gov with Post Graduate Institute of Medical Education and Research, Chandigarh as lead sponsor.

NCT NCT04856111
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04856111 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Study of the Efficacy and Safety of Pirfenidone vs. Nintedanib in the Treatment of Fibrotic Lung Disease After Coronavirus Disease-19 Pneumonia
Lead sponsor
Post Graduate Institute of Medical Education and Research, Chandigarh
Phase
Phase 4
Overall status
Unknown status
Start date
March 17, 2021
Completion date
November 30, 2022
Enrollment
48 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

novel coronavirus-induced lung fibrosis